Spyre Therapeutics (SYRE) Non Operating Income (2015 - 2026)
Spyre Therapeutics (SYRE) posted Non Operating Income of -$23.4 million for Q1 2026, down 336.06% on a QoQ basis from -$5.4 million in Q4 2025, and down 366.14% year-over-year from $8.8 million in Q1 2025.
Spyre Therapeutics (SYRE) Non Operating Income (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Non Operating Income history runs 12 years deep, the most recent figure standing at -$23.4 million for Q1 2026.
- Quarterly Non Operating Income fell 366.14% year-over-year to -$23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (up 308.93% YoY) and the FY2025 annual result came in at $54.3 million, up 8972.45% from the prior year.
- Non Operating Income was -$23.4 million for Q1 2026 at Spyre Therapeutics, down from -$5.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $45.7 million in Q3 2025 and bottomed at -$57.8 million in Q2 2023.
- A 5-year average of -$3.8 million and a median of $312000.0 in 2022 frame the typical range for Non Operating Income.
- Peak annual rise in Non Operating Income reached 6860.0% in 2023, while the deepest fall reached 53153.21% in 2023.
- Spyre Therapeutics' Non Operating Income stood at $378000.0 in 2022, then plunged by 4667.72% to -$17.3 million in 2023, then soared by 128.72% to $5.0 million in 2024, then sank by 208.07% to -$5.4 million in 2025, then slumped by 336.06% to -$23.4 million in 2026.
- Business Quant data shows SYRE's Non Operating Income at -$23.4 million in Q1 2026, -$5.4 million in Q4 2025, and $45.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -23.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.36 Mn |
| Dec 31, 2025 | -5.36 Mn |
| Sep 30, 2025 | 45.71 Mn |
| Jun 30, 2025 | 5.22 Mn |
| Mar 31, 2025 | 8.78 Mn |
| Dec 31, 2024 | 4.96 Mn |
| Sep 30, 2024 | -13.62 Mn |
| Jun 30, 2024 | 5.31 Mn |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | -17.27 Mn |
| Sep 30, 2023 | -21.77 Mn |
| Jun 30, 2023 | -57.83 Mn |
| Mar 31, 2023 | 348,000.00 |
| Dec 31, 2022 | 378,000.00 |
| Sep 30, 2022 | 312,000.00 |
| Jun 30, 2022 | 109,000.00 |
| Mar 31, 2022 | 5,000.00 |
| Dec 31, 2021 | 19,000.00 |
| Sep 30, 2021 | 12,000.00 |
| Jun 30, 2021 | -33,000.00 |